3 best performing ASX shares in the week of 2 May 2022
Marc Kennis, May 9, 2022
Best performing ASX shares
The three best performing ASX shares in the week of 2 May 2022 were Metalstech (ASX:MTC), up 44%, Red Sky Energy (ASX:ROG), up 27.3%, and Castile Resources (ASX:CST), up 25%.
GET A 30-DAY FREE TRIAL TO STOCKS DOWN UNDER
1. Metalstech (ASX:MTC)
Industry: Resources
Metalstech Limited (ASX:MTC) is involved in gold and lithium exploration. The company has two major projects Sturec Gold Project and Cancet Lithium Project.
Market Cap: $60m
12 month high / low: $0.12 – $0.80
2. Red Sky Energy (ASX:ROG)
Industry: Energy
Red Sky Energy Limited (ASX:ROG) is an oil and gas exploration company that is focused on coal seam gas (CSG). The Company continues to review other opportunities in Australasia and South East Asia.
Market Cap: $37M
12 month high / low: $0.0045 – $0.013
3. Castile Resources (ASX:CST)
Industry: Resources
Castile Resources Ltd (ASX:CST) is in the business of mineral exploration and development in the Northern Territory. Castile’s strategy is to explore the Projects, including by undertaking follow up drilling and identifying and exploring exploration targets in project areas that have not been effectively tested. It holds interest in “The Rover Project” and “The Warumpi Project”.
Market Cap: $45m
12 month high / low: $0.155 – $0.30
Learn more about ASX-listed stocks with
Stocks Down Under!
Subscribe to Stocks Down Under today!
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Can Gold Hit $4,000 in 2025? These 5 ASX Stocks Could Soar if It Does
In our view, the question isn’t just whether gold can hit $4,000 an ounce in 2025; it’s about what happens…
Qantas Board Shake-Up: Is Investor Pressure Finally Taking Effect?
Qantas Airways, Australia’s flagship airline, has long been a symbol of national pride, maintaining a central position in the country’s…
Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product
Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…